Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Thyroid cancer
Stage/Subtype:  stage IV follicular thyroid cancer
Trial Type:  Treatment
Trial Status:  Active
Results 1-25 of 34 for your search:
Start Over
rAd-p53 Gene Therapy for Advanced Malignant Thyroid Tumors
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 85
Sponsor: Pharmaceutical / Industry
Protocol IDs: rAd-p53-003, NCT00902122
Medico-Economic Comparison of Four Strategies of Radioiodine Ablation in Thyroid Carcinoma Patients
Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: Estimabl, CSET 1216, NCT00435851
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BBI608-201, NCT01325441
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing Human Thyroglobulin to People With Thyroglobulin Expressing Thyroid Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 18 to 66
Sponsor: NCI
Protocol IDs: 150090, 15-C-0090, NCT02390739
Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 12 to less than 18
Sponsor: Pharmaceutical / Industry
Protocol IDs: E7080-G000-207, 2013-005534-38, NCT02432274
Pemetrexed + Paclitaxel in Patients With Recurrent/Advanced Thyroid Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: Panthera, NCT00786552
Study of External Beam Radiotherapy to Thyroid Carcinoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: NCCCTS-09-436, NCT01173289
A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Cell Origin
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 100041, 10-C-0041, NCT01182285
A Trial of Pasireotide and Everolimus in Adult Patients With Radioiodine-Refractory Differentiated and Medullary Thyroid Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: IRB00041909, WCI1777-09, NCT01270321
Redifferentiation Therapy Using Alpha Lipoic Acid in Thyroid Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 20 to 75
Sponsor: Other
Protocol IDs: AMC_THY_001, NCT01396733
Pioglitazone in Follicular or Follicular Variant of Papillary Thyroid Cancers
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: 2011.097, NCT01655719
Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: OSU-12064, NCI-2012-01700, NCCNGSK20008, NCT01723202
Nintedanib(BIBF1120) in Thyroid Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: EORTC-1209, 2012-004295-19, NCT01788982
Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2013-00554, 2012C0101, RU241210I, OSU 12154, 9312, N01CM00039, N01CM00070, N01CM00071, N01CM00099, P30CA016058, NCT01811212
Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: PAZOTHYR, 2012-003162-41, NCT01813136
Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1
Phase: Phase II
Type: Treatment
Status: Active
Age: 1 and over
Sponsor: Other
Protocol IDs: UC-0105/1303, 2013-000885-13, NCT02034981
A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UPCC 28313, NCT02041260
Safety and Efficacy of Sorafenib in Patients With Advanced Thyroid Cancer: a Phase II Clinical Study
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: 410-30610-258, NCT02084732
Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Thyroid Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: A091302, U10CA180821, NCI-2014-00623, NCT02143726
Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2014-01106, 13-157, 9446, P30CA008748, NCT02152995
A Multicenter Phase II Pilot Open Label
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2012-748, NCT01830504
Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UC-0105/1401, 2014 001225 33, NCT02304809
Phase II Study of Tipifarnib in Advanced Cancers With HRAS Mutations
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: KO-TIP-001, NCT02383927
Efficacy of Radium 223 in Radioactive Iodine Refractory Bone Metastases From Differentiated Thyroid Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2014-001070-34, 2014/2110, NCT02390934
Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: RU241306I, NCI-2015-00277, P30CA015083, NCT02393690
Start Over